Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Blaakaer

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Acta Endocrinologica|August 1, 1992
The pituitary-gonadal axis in women with benign or malignant ovarian tumorsJ Blaakaer, H Djursing, U Hørding, et al.
Gynecologic Oncology|March 6, 2009
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumorsF D Begum, E Høgdall, S K Kjaer, et al.
Cancer Causes & Control : CCC|October 1, 2013
Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancerM T Faber, A Jensen, K Frederiksen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 1, 1994
Sex hormone binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditionsM M Cornelisse, P E Bennett, M Christiansen, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
Immunoreactive inhibin-production in post-menopausal women with malignant epithelial ovarian tumorsJ Blaakaer, S Micic, I D Morris, et al.
Clinical Chemistry|May 1, 1999
OVX1 radioimmunoassay results are dependent on the method of sample collection and storageE V Hogdall, C K Hogdall, S K Kjaer, et al.
Endocrine-Related Cancer|December 3, 2005
Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotesS E Bojesen, S K Kjaer, E V S Høgdall, et al.
Genitourinary Medicine|April 1, 1996
Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital wartsD K Armstrong, R D Maw, W W Dinsmore, et al.
British Journal of Cancer|February 26, 2009
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancerL Quaye, H Song, S J Ramus, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Acta Endocrinologica|August 1, 1992
The pituitary-gonadal axis in women with benign or malignant ovarian tumorsJ Blaakaer, H Djursing, U Hørding, et al.
Gynecologic Oncology|March 6, 2009
Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumorsF D Begum, E Høgdall, S K Kjaer, et al.
Cancer Causes & Control : CCC|October 1, 2013
Oral contraceptive use and impact of cumulative intake of estrogen and progestin on risk of ovarian cancerM T Faber, A Jensen, K Frederiksen, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|March 1, 1994
Sex hormone binding globulin phenotypes: their detection and distribution in healthy adults and in different clinical conditionsM M Cornelisse, P E Bennett, M Christiansen, et al.
European Journal of Obstetrics, Gynecology, and Reproductive Biology|December 15, 1993
Immunoreactive inhibin-production in post-menopausal women with malignant epithelial ovarian tumorsJ Blaakaer, S Micic, I D Morris, et al.
Clinical Chemistry|May 1, 1999
OVX1 radioimmunoassay results are dependent on the method of sample collection and storageE V Hogdall, C K Hogdall, S K Kjaer, et al.
Endocrine-Related Cancer|December 3, 2005
Increased risk of ovarian cancer in integrin beta3 Leu33Pro homozygotesS E Bojesen, S K Kjaer, E V S Høgdall, et al.
Genitourinary Medicine|April 1, 1996
Combined therapy trial with interferon alpha-2a and ablative therapy in the treatment of anogenital wartsD K Armstrong, R D Maw, W W Dinsmore, et al.
British Journal of Cancer|February 26, 2009
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancerL Quaye, H Song, S J Ramus, et al.
Pageof 4